Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

A-H Premium Weekly: Healthcare Led Premium Decline

A-H Premium Weekly: Real Estate, Industrials, Utilities Led the Decline

A-H Premium Weekly: China Southern, Shanghai Junshi, Shanghai Haohai, Shanghai Fudan

A-H Premium Weekly: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink

A/H Premium Weekly: Arb Opportunities Last Week

A/H Premium Weekly: BYD, Xinjiang Gold Wind, Ganfeng Lithium

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Real estate / Quantitative Analysis

China Communications Construction (1800 HK)

<ul>
<li>We analyse the changes of A/H premium on 138 stocks over the last week.</li>
<li>A-H premium decline of 1.7ppt last week was led by the health care consumer discretionary, and information technology sectors. </li>
<li>We highlight stocks at 52w high A-H premium: Flat Glass, Shandong Chenming Paper, CCC , Tianjin Capital, QHD Port, Beijing North Star, Shenzhen HepaLink.</li>
</ul>


We analyse the changes of A/H premium on 138 stocks over the last week.
A-H premium decline of 1.7ppt last week was led by the health care consumer discretionary, and information technology sectors. 
We highlight stocks at 52w high A-H premium: Flat Glass, Shandong Chenming Paper, CCC , Tianjin Capital, QHD Port, Beijing North Star, Shenzhen HepaLink.


Shenzhen HepaLink Pharmaceutical (H) (9989 HK)

A-H Premium Weekly: Real Estate at 52 Week High